Drug Profile
Research programme: cancer therapeutics - Enlibrium
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator University of California at Los Angeles
- Developer Enlibrium
- Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
- Mechanism of Action Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 03 Dec 2015 Preclinical trials in Cancer in USA (unspecified route)